They observed a 10-fold increase in the numbers of specific T cells and demonstrated that GITR signaling directly acted on CD8+ T cells, and, in a CMS5 sarcoma model, GITRL inhibited tumor growth which was dependent on the presence of CD8+, but not CD4+ T cells. The gene discussed is CD8A; the disease is neoplasm.